{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:37Z","timestamp":1791219397305,"version":"4.1.0"},"posted":{"date-parts":[[2026,5,25]]},"group-title":"In Review","reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,20]]},"abstract":"<title>Abstract<\/title>\n                <p>The cytidine analog Azvudine (Azv) showed promising therapeutic effects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), leading to its conditional authorization as a COVID-19 treatment in China. Once Azvudine enters infected cells, it is converted to the active form, Azvudine-triphosphate, which has been shown to inhibit polymerases of several viruses. Here we show that when Azvudine is incorporated into RNA by the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), it hinders incorporation of the subsequent nucleotide. However, the 3\u2019-Azv-terminated RNA does not show any resistance to the SARS-CoV-2 proofreading exonuclease (ExoN). Furthermore, we found that the incorporation of Azvudine at the penultimate position of the RNA prevents RNA cleavage by the ExoN. These findings may provide molecular insight for the development of novel nucleotide analogs that can inhibit RdRp and resist the viral proofreading mechanism of coronaviruses.<\/p>","DOI":"10.21203\/rs.3.rs-9465547\/v1","type":"posted-content","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:46:32Z","timestamp":1779713192000},"source":"Crossref","is-referenced-by-count":0,"title":["RNA with Azvudine Incorporated One Nucleotide Upstream of 3\u2019-End Resists Cleavage by SARS-CoV-2 Proofreading Exonuclease"],"prefix":"10.21203","author":[{"given":"Ying Tong","family":"Yue","sequence":"first","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kao","family":"Lin","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjuan","family":"Tao","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Li","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Peng","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Teplova","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Kumar","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Morozova","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Kalachikov","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Russo","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinshaw J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Ju","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman S","year":"2018","unstructured":"Venkataraman, S., Prasad, B. V. L. S. & Selvarajan, R. RNA dependent RNA polymerases: insights from structure, function and evolution. Viruses 10, 76 (2018).","journal-title":"Viruses"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao Y","year":"2020","unstructured":"Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779\u2013782 (2020).","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fmicb.2019.01945","article-title":"A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses","volume":"10","author":"Jia H","year":"2019","unstructured":"Jia, H. & Gong, P. A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Front. Microbiol. 10, 1945 (2019).","journal-title":"Front. Microbiol."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2023.02.011","article-title":"Genetic conservation across SARS-CoV-2 non-structural proteins\u2014insights into possible targets for treatment of future viral outbreaks","volume":"581","author":"Kandwal S","year":"2023","unstructured":"Kandwal, S. & Fayne, D. Genetic conservation across SARS-CoV-2 non-structural proteins\u2014insights into possible targets for treatment of future viral outbreaks. Virology 581, 97\u2013115 (2023).","journal-title":"Virology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"Velthuis AJW","year":"2014","unstructured":"te Velthuis, A. J. W. Common and unique features of viral RNA-dependent polymerases. Cell. Mol. Life Sci. 71, 4403\u20134420 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"104857","DOI":"10.1016\/j.antiviral.2020.104857","article-title":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19","volume":"180","author":"Jockusch S","year":"2020","unstructured":"Jockusch, S. et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res. 180, 104857 (2020).","journal-title":"Antiviral Res."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"105501","DOI":"10.1016\/j.antiviral.2022.105501","article-title":"Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2","volume":"210","author":"Shannon A","year":"2023","unstructured":"Shannon, A. & Canard, B. Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2. Antiviral Res. 210, 105501 (2023).","journal-title":"Antiviral Res."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger F","year":"2021","unstructured":"Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740\u2013746 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.3390\/ijms232012649","article-title":"Inhibition of viral RNA-dependent RNA polymerases by nucleoside inhibitors: an illustration of the unity and diversity of mechanisms","volume":"23","author":"Barik S","year":"2022","unstructured":"Barik, S. Inhibition of viral RNA-dependent RNA polymerases by nucleoside inhibitors: an illustration of the unity and diversity of mechanisms. Int. J. Mol. Sci. 23, 12649 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen HS","year":"2020","unstructured":"Hillen, H. S. et al. Structure of replicating SARS-CoV-2 polymerase. Nature 584, 154\u2013156 (2020).","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien M","year":"2020","unstructured":"Chien, M. et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J. Proteome Res. 19, 4690\u20134697 (2020).","journal-title":"J. Proteome Res."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e00674","DOI":"10.1002\/prp2.674","article-title":"Nucleotide analogues as inhibitors of viral polymerases","volume":"8","author":"Ju J","year":"2020","unstructured":"Ju, J. et al. Nucleotide analogues as inhibitors of viral polymerases. Pharmacol. Res. Perspect. 8, e00674 (2020).","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2020.08.116","article-title":"RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19","volume":"538","author":"Jiang Y","year":"2021","unstructured":"Jiang, Y., Yin, W. & Xu, H. E. RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19. Biochem. Biophys. Res. Commun. 538, 47\u201353 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e70968","DOI":"10.7554\/eLife.70968","article-title":"Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective","volume":"10","author":"Seifert M","year":"2021","unstructured":"Seifert, M. et al. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective. eLife 10, e70968 (2021).","journal-title":"eLife"},{"key":"ref15","author":"Moeller NH","year":"2022","unstructured":"Moeller, N. H. et al. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. Proc. Natl. Acad. Sci. U.S.A. 119, e2106379119 (2022)."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon CJ","year":"2020","unstructured":"Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 295, 6785\u20136797 (2020).","journal-title":"J. Biol. Chem."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic G","year":"2021","unstructured":"Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, 279 (2021).","journal-title":"Nat. Commun."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"16577","DOI":"10.1038\/s41598-020-73641-9","article-title":"Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by remdesivir","volume":"10","author":"Jockusch S","year":"2020","unstructured":"Jockusch, S. et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by remdesivir. Sci. Rep. 10, 16577 (2020).","journal-title":"Sci. Rep."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1016\/j.ejmech.2011.06.020","article-title":"Synthesis of new 2\u2032-deoxy-2\u2032-fluoro-4\u2032-azido nucleoside analogues as potent anti-HIV agents","volume":"46","author":"Wang Q","year":"2011","unstructured":"Wang, Q. et al. Synthesis of new 2\u2032-deoxy-2\u2032-fluoro-4\u2032-azido nucleoside analogues as potent anti-HIV agents. Eur. J. Med. Chem. 46, 4178\u20134183 (2011).","journal-title":"Eur. J. Med. Chem."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e105617","DOI":"10.1371\/journal.pone.0105617","article-title":"Azvudine, a novel nucleoside reverse transcriptase inhibitor, showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro","volume":"9","author":"Wang RR","year":"2014","unstructured":"Wang, R. R. et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor, showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS ONE. 9, e105617 (2014).","journal-title":"PLoS ONE"},{"key":"ref21","first-page":"e00204","article-title":"The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses","volume":"94","author":"Xu N","year":"2020","unstructured":"Xu, N. et al. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J. Virol. 94, e00204\u2013e00220 (2020).","journal-title":"J. Virol."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/acs.accounts.1c00697","article-title":"4'-Modified nucleosides for antiviral drug discovery: achievements and perspectives","volume":"55","author":"Chang J","year":"2022","unstructured":"Chang, J. 4'-Modified nucleosides for antiviral drug discovery: achievements and perspectives. Acc. Chem. Res. 55, 565\u2013578 (2022).","journal-title":"Acc. Chem. Res."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1074\/jbc.M708929200","article-title":"2'-Deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups","volume":"283","author":"Klumpp K","year":"2008","unstructured":"Klumpp, K. et al. 2'-Deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups. J. Biol. Chem. 283, 2167\u20132175 (2008).","journal-title":"J. Biol. Chem."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e2001435","DOI":"10.1002\/advs.202001435","article-title":"A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study","volume":"7","author":"Ren Z","year":"2020","unstructured":"Ren, Z. et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv. Sci. 7, e2001435 (2020).","journal-title":"Adv. Sci."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"101981","DOI":"10.1016\/j.eclinm.2023.101981","article-title":"Oral azvudine for hospitalized patients with COVID-19 and pre-existing conditions: a retrospective cohort study","volume":"59","author":"Sun Y","year":"2023","unstructured":"Sun, Y. et al. Oral azvudine for hospitalized patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine 59, 101981 (2023).","journal-title":"EClinicalMedicine"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"e090230","DOI":"10.1136\/bmjopen-2024-090230","article-title":"Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China","volume":"15","author":"Wang F","year":"2025","unstructured":"Wang, F. et al. Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China. BMJ Open. 15 (6), e090230 (2025).","journal-title":"BMJ Open."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Oral azvudine: thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Wu L","year":"2021","unstructured":"Wu, L. et al. Oral azvudine: thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal. Transduct. Target. Ther. 6, 414 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref28","first-page":"110238","article-title":"Azvudine alleviates SARS-CoV-2-induced inflammation by targeting myeloperoxidase in NETosis","volume":"35","author":"Li Y","year":"2024","unstructured":"Li, Y. et al. Azvudine alleviates SARS-CoV-2-induced inflammation by targeting myeloperoxidase in NETosis. Chin. Chem. Lett. 35, 110238 (2024).","journal-title":"Chin. Chem. Lett."},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"ugaf029","DOI":"10.1093\/narmme\/ugaf029","article-title":"Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-\u03b2-fluoro-4'-azidocytidine or azvudine","volume":"2","author":"Lee HW","year":"2025","unstructured":"Lee, H. W. et al. Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-\u03b2-fluoro-4'-azidocytidine or azvudine. NAR Mol. Med. 2 (3), ugaf029 (2025).","journal-title":"NAR Mol. Med."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41418-021-00900-1","article-title":"The NSP14\/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target","volume":"29","author":"Rona G","year":"2022","unstructured":"Rona, G. et al. The NSP14\/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target. Cell. Death Differ. 29, 285\u2013292 (2022).","journal-title":"Cell. Death Differ."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","article-title":"Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design","volume":"23","author":"Malone B","year":"2022","unstructured":"Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell. Biol. 23, 21\u201339 (2022).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan W","year":"2022","unstructured":"Yan, W. et al. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal. Transduct. Target. Ther. 7, 26 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s42003-022-03101-9","article-title":"Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture","volume":"5","author":"Wang X","year":"2022","unstructured":"Wang, X. et al. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun. Biol. 5, 154 (2022).","journal-title":"Commun. Biol."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.3390\/molecules25235695","article-title":"Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge","volume":"25","author":"Picarazzi F","year":"2020","unstructured":"Picarazzi, F. et al. Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge. Molecules 25, 5695 (2020).","journal-title":"Molecules"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9465547\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9465547\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:24Z","timestamp":1791216444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9465547\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":34,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9465547\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-026-73194-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,5,25]]},"subtype":"preprint"}}